Nowhere to Hide: Radio-faint AGN in the GOODS-N field. I. Initial catalogue and radio properties

(Abridged) Conventional radio surveys of deep fields ordinarily have arc-second scale resolutions often insufficient to reliably separate radio emission in distant galaxies originating from star-formation and AGN-related activity. Very long baseline interferometry (VLBI) can offer a solution by identifying only the most compact radio emitting regions in galaxies at cosmological distances where the high brightness temperatures (in excess of $10^5$ K) can only be reliably attributed to AGN activity. We present the first in a series of papers exploring the faint compact radio population using a new wide-field VLBI survey of the GOODS-N field. The unparalleled sensitivity of the European VLBI Network (EVN) will probe a luminosity range rarely seen in deep wide-field VLBI observations, thus providing insights into the role of AGN to radio luminosities of the order $10^{22}~\mathrm{W\,Hz^{-1}}$ across cosmic time. The newest VLBI techniques are used to completely cover an entire 7'.5 radius area to milliarcsecond resolutions, while bright radio sources ($S > 0.1$ mJy) are targeted up to 25 arcmin from the pointing centre. Multi-source self-calibration, and a primary beam model for the EVN array are used to correct for residual phase errors and primary beam attenuation respectively. This paper presents the largest catalogue of VLBI detected sources in GOODS-N comprising of 31 compact radio sources across a redshift range of 0.11-3.44, almost three times more than previous VLBI surveys in this field. We provide a machine-readable catalogue and introduce the radio properties of the detected sources using complementary data from the e-MERLIN Galaxy Evolution survey (eMERGE).Comment: 15 pages, 8 figures, accepted in A&A. Machine-readable table available upon reques

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

Contains fulltext : 97893.pdf (publisher's version ) (Open Access)ABSTRACT: BACKGROUND: Polycystic liver disease (PLD) is defined as having more than 20 liver cysts and can present as a severe and disabling condition. Most symptoms are caused by the mass effect of the liver size and include abdominal pain and distension. The somatostatin analogues octreotide and lanreotide have proven to reduce polycystic liver volume. mTOR inhibitors such as everolimus inhibit cell proliferation and might thereby reduce growth of liver cysts. This trial aims to assess the benefit of combination therapy of everolimus and octreotide compared to octreotide monotherapy. In this study we present the structure of the trial and the characteristics of the included patients. METHODS/DESIGN: This is a randomized open-label clinical trial comparing the effect of 12 months of everolimus and octreotide to octreotide monotherapy in PLD patients. Primary outcome is change in liver volume determined by CT-volumetry. Secondary outcomes are changes in abdominal symptoms and quality of life. Moreover, safety and tolerability of the drugs will be assessed. DISCUSSION: This trial will compare the relative efficacy of combination therapy with octreotide and everolimus to octreotide monotherapy. Since they apply to different pathways of cystogenesis we expect that combining octreotide and everolimus will result in a cumulative reduction of polycystic liver volume. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT01157858

The SFXC software correlator for Very Long Baseline Interferometry: Algorithms and Implementation

In this paper a description is given of the SFXC software correlator, developed and maintained at the Joint Institute for VLBI in Europe (JIVE). The software is designed to run on generic Linux-based computing clusters. The correlation algorithm is explained in detail, as are some of the novel modes that software correlation has enabled, such as wide-field VLBI imaging through the use of multiple phase centres and pulsar gating and binning. This is followed by an overview of the software architecture. Finally, the performance of the correlator as a function of number of CPU cores, telescopes and spectral channels is shown.Comment: Accepted by Experimental Astronom

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

Contains fulltext : 109282.pdf (publisher's version ) (Open Access)BACKGROUND: A large proportion of patients with autosomal dominant polycystic kidney disease (ADPKD) suffers from polycystic liver disease. Symptoms arise when liver volume increases. The somatostatin analogue lanreotide has proven to reduce liver volume in patients with polycystic liver disease. However, this study also included patients with isolated polycystic liver disease (PCLD). The RESOLVE trial aims to assess the efficacy of lanreotide treatment in ADPKD patients with symptomatic polycystic livers. In this study we present the design of the RESOLVE trial. METHODS/DESIGN: This open-label clinical trial evaluates the effect of 6 months of lanreotide in ADPKD patients with symptomatic polycystic livers. Primary outcome is change in liver volume determined by computerised tomography-volumetry. Secondary outcomes are changes in total kidney volume, kidney intermediate volume and renal function. Furthermore, urinary (NGAL, alpha1-microglobulin, KIM-1, H-FABP, MCP-1) and serum (fibroblast growth factor 23) biomarkers associated with ADPKD disease severity are assessed to investigate whether these biomarkers predict treatment responses to lanreotide. Moreover, safety and tolerability of the drug in ADPKD patients will be assessed. DISCUSSION: We anticipate that lanreotide is an effective therapeutic option for ADPKD patients with symptomatic polycystic livers and that this trial aids in the identification of patient related factors that predict treatment response. TRIAL REGISTRATION NUMBER: Clinical trials.gov NCT01354405

Дослідження ефективності управління примежовим шаром на опорній поверхні шляхової структури перспективних транспортних технологій Maglev

Исследованы физические процессы управления пограничным слоем на профилированной поверхности путевой структуры перспективных транспортных технологий. Установлены закономерности влияния параметров управления пограничным слоем на распределение скоростей на путевой структуре.The physical processes of control are investigational by a frontier layer on the profiled surface of the ground structure of perspective transport technologies. Conformities to law of influence of control parameters are set by a frontier layer on distribution of speeds on the ground structure